0001654954-22-014263.txt : 20221026
0001654954-22-014263.hdr.sgml : 20221026
20221026214120
ACCESSION NUMBER: 0001654954-22-014263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221026
FILED AS OF DATE: 20221026
DATE AS OF CHANGE: 20221026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: tsai chun-hsien
CENTRAL INDEX KEY: 0001859363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41461
FILM NUMBER: 221334654
MAIL ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ainos, Inc.
CENTRAL INDEX KEY: 0001014763
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 751974352
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 858-869-2986
MAIL ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
FORMER COMPANY:
FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC
DATE OF NAME CHANGE: 19960516
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2022-10-26
0001014763
Ainos, Inc.
AIMD
0001859363
tsai chun-hsien
8880 RIO SAN DIEGO DRIVE, SUITE 800
SAN DIEGO
CA
92108
true
true
CEO, PRESIDENT, CHAIRMAN
Common Stock
2022-10-26
4
A
false
333333
1.89
A
355599
D
Common Stock
22266
D
RSU
1.89
2022-10-26
4
C
false
5000000
1.89
D
2022-09-30
2022-10-26
COMMON
333333
0
D
RSU
2022-10-24
4
A
false
50000
D
COMMON
50000
50000
D
The amount of common stock previously reported totaling 333,986 shares is hereby adjusted to 22,266 shares giving effect to a 15-to-1 Reverse Stock Split made effective on August 8, 2022 (the "Reverse Stock Split").
This reported transaction represents the conversion of 5,000,000 Restricted Stock Units (the "RSUs") adjusted to 333,000 shares giving effect to the Reverse Stock Split. The RSUs were originally granted pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") under the Company's 2021 Stock Incentive Plan. The converted shares underlying the RSUs vested on September 30, 2022 and may not be sold within 6 months of the grant date.
This reported transaction represents the settlement of 5,000,000 RSUs adjusted to 333,333 common stock after giving effect the Reverse Stock Split.
This reported transaction represents the granting of 50,000 Restricted Stock Units (the "RSUs"). The RSUs were originally authorized pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") and under the Company's 2021 Stock Incentive Plan. The RSUs will vest in increments of 15% on 4/24/23 and 10/24/23, 30% on 10/24/24 and 40% on 10/24/25, subject to normal and customary termination events.
/s/ John Junyong Lee POA for Chun-Hsien Tsai
2022-10-26